Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

823372

registered interest
date	16/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Ovarian Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the timetable is for the introduction of new medicines to help prevent the spread of ovarian cancer.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	122855
answer	answer is ministerial correction date of answer 24/01/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) has published a number of technology appraisal guidance documents on the treatment of ovarian cancer. NICE technology appraisal guidance makes recommendations for the National Health Service on whether drugs and treatments represent a clinically and cost effective use of resources. NHS commissioners are legally required to fund drugs and treatments recommended through the technology appraisal programme within three months.</p><p> </p><p>NICE has positively appraised guidance on use of “Paclitaxel in the treatment of ovarian cancer” (TA:55), published in May 2005; “Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy” (TA:381), published in January 2016; and, “Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer” (TA:389), published in April 2016.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 24/01/2018 12:11:27 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

823373

registered interest
date	16/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with GPs and clinical bodies on improving the rate at which diabetics take their medications.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	122856
answer	answer is ministerial correction date of answer 24/01/2018 answer text <p>The appropriate use of prescribed medication for diabetes, and any actions to support this, can form part of the annual reviews between general practitioners and their diabetes patients. NHS England is also overseeing the investment of diabetes transformation funding towards improved access to diabetes structured education within individual clinical commissioning groups.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 24/01/2018 12:02:40 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

823445

registered interest
date	16/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Influenza: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the availability of stocks of flu vaccines in (a) York and (b) England.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	122923
answer	answer is ministerial correction date of answer 24/01/2018 answer text <p>Flu vaccines for people aged 18 years and older are procured directly from manufacturers and suppliers by providers. The procurement and distribution of flu vaccines for the children’s aspect of the national flu programme is managed by Public Health England.</p><p> </p><p>Flu vaccine remains available to order from manufacturers and suppliers across England for both the adult and the children’s aspects of the national flu immunisation programme.</p><p> </p><p>Officials are continuously monitoring the flu vaccine supply landscape to enable timely and appropriate action to be taken in the event that demand begins to outweigh the amount of flu vaccine that is currently available to patients.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 122924 question first answered 24/01/2018 11:59:58 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

823446

registered interest
date	16/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Influenza: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to increase the supply of flu vaccines to areas in the event that there are shortfalls of such vaccines during Winter 2017-18.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	122924
answer	answer is ministerial correction date of answer 24/01/2018 answer text <p>Flu vaccines for people aged 18 years and older are procured directly from manufacturers and suppliers by providers. The procurement and distribution of flu vaccines for the children’s aspect of the national flu programme is managed by Public Health England.</p><p> </p><p>Flu vaccine remains available to order from manufacturers and suppliers across England for both the adult and the children’s aspects of the national flu immunisation programme.</p><p> </p><p>Officials are continuously monitoring the flu vaccine supply landscape to enable timely and appropriate action to be taken in the event that demand begins to outweigh the amount of flu vaccine that is currently available to patients.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 122923 question first answered 24/01/2018 11:59:58 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

823505

registered interest
date	16/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescription Drugs: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 18 December 2017 to Question 119906, what steps he took to ascertain why the market price of amlodipine 5mg tablets was above the reimbursement price listed in the Drug Tariff prior to granting a concessionary price.
tabling member constituency	Fylde
tabling member printed	Mark Menzies
uin	122976
answer	answer is ministerial correction date of answer 19/01/2018 answer text <p>Before granting a concessionary price we contact suppliers to ascertain that the product was not available at or below the reimbursement price listed in the Drug Tariff. While a specific assessment was not made as to why this particular product was not available at or below the reimbursement price listed in the Drug Tariff, we are aware of a number of reasons for the pressure in the supply chain generally.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/01/2018 14:15:03 answering member 4067 label Biography information for Steve Brine
tabling member	3998 label Biography information for Mark Menzies

823518

registered interest
date	16/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Life Sciences
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps are being taken to ensure that the UK enters the top quartile of comparator countries for the speed of adoption and overall uptake of innovative treatments as recommended in the Life Sciences Industrial Strategy.
tabling member constituency	Reigate
tabling member printed	Crispin Blunt
uin	122988
answer	answer is ministerial correction date of answer 24/01/2018 answer text <p>Comparisons of uptake of medicines between different countries with different health systems are difficult and should be treated with caution. However, we are committed to working with industry on this issue and share the ambition to maximise the appropriate use of innovation in our system and tackle unwarranted variation in uptake. The Government and industry are currently working together through a series of workshops that will provide the foundation for the next medicines pricing scheme, and discussions around uptake, adoption and metrics have been a feature of those early meetings.</p><p> </p><p>The recent Government and partner bodies response to the Accelerated Access Review sets out how we will work with industry and the health system to create a streamlined and sophisticated approvals system so that cost-effective breakthrough products – be they drugs, devices, digital or diagnostics – can get into the National Health Service as fast as possible.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 24/01/2018 11:57:48 answering member 4067 label Biography information for Steve Brine
tabling member	104 label Biography information for Crispin Blunt

823522

registered interest
date	16/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Life Sciences
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps are being taken to update and evolve value assessments of drugs, medical devices and diagnostics, as recommended in the Life Sciences Industrial Strategy.
tabling member constituency	Reigate
tabling member printed	Crispin Blunt
uin	122991
answer	answer is ministerial correction date of answer 24/01/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) is committed to playing its part in delivering the vision set out in the Life Sciences Industrial Strategy. Ensuring that appraisals are fit for purpose in a fast-changing sector is critical. NICE has recently taken steps to do this by introducing changes to its processes to support faster access to the most effective treatments, while addressing affordability issues. In addition, NICE has recently consulted on further changes to streamline its technology appraisal processes so that it is better able to develop new guidance on innovative drugs and medical technologies.</p><p> </p><p>As set out in the response to the Accelerated Access Review, we are also introducing a new Accelerated Access Pathway, to streamline regulatory and market access decisions for a small number of products, getting breakthrough products that we believe will be truly transformative to patients even more quickly.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 24/01/2018 16:38:26 answering member 4067 label Biography information for Steve Brine
tabling member	104 label Biography information for Crispin Blunt

823523

registered interest
date	16/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the extension of Orkambi's licence to treat patients aged six and over, what support his Department is giving to further negotiations among NICE, NHS England and the drug manufacturer, Vertex, on access to that medicine for people with cystic fibrosis.
tabling member constituency	Reigate
tabling member printed	Crispin Blunt
uin	122992
answer	answer is ministerial correction date of answer 24/01/2018 answer text <p>The Department wants patients with cystic fibrosis to benefit from clinically and cost effective treatments, and we welcome the on-going dialogue between Vertex and NHS England to pursue a deal that would make Orkambi available to National Health Service patients.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 24/01/2018 12:13:27 answering member 4067 label Biography information for Steve Brine
tabling member	104 label Biography information for Crispin Blunt

823525

registered interest
date	16/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescriptions: Adoption Leave
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 16 January 2018 to Question 122208, if he will make it his policy to conduct an assessment of the potential merits of issuing maternity exemption certificates to people taking adoption leave.
tabling member constituency	Oxford West and Abingdon
tabling member printed	Layla Moran
uin	122994
answer	answer is ministerial correction date of answer 19/01/2018 answer text <p>The Department has no plans to undertake an assessment of the potential merits of issuing maternity exemption certificates to people taking adoption leave. Almost 90% of prescription items are free on the National Health Service in England and for those who do not qualify for an exemption, prescription prepayment certificates are available. A holder of a 12 month certificate can get all the prescriptions they need for just £2 per week.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/01/2018 14:16:04 answering member 4067 label Biography information for Steve Brine
tabling member	4656 label Biography information for Layla Moran

823588

registered interest
date	16/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an estimate of the average yearly cost to patients of paying for prescribed asthma medication.
tabling member constituency	Warrington North
tabling member printed	Helen Jones
uin	123051
answer	answer is ministerial correction date of answer 24/01/2018 answer text <p>The Department has made no such estimate. FP10 prescriptions forms do not specify what clinical indication the medicine/device is being prescribed for, therefore the requested data is not collected.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 24/01/2018 12:15:06 answering member 4067 label Biography information for Steve Brine
tabling member	432 label Biography information for Helen Jones